Suppr超能文献

泛癌分析揭示了人类肿瘤中SETDB1的基因组学和临床特征。

Pancancer Analyses Reveal Genomics and Clinical Characteristics of the SETDB1 in Human Tumors.

作者信息

Lin Xin, Xiao Min, Chen Zhitao, Ding Chenchen, Zhang Ting, Li Qiyong

机构信息

Department of Hepatobiliary Surgery, Shulan (Hangzhou) Hospital Affiliated to Zhejiang Shuren University Shulan International Medical College, Hangzhou, China.

School of Medicine, Zhejiang University, Hangzhou, China.

出版信息

J Oncol. 2022 May 23;2022:6115878. doi: 10.1155/2022/6115878. eCollection 2022.

Abstract

BACKGROUND

Malignant tumor is one of the most common diseases that seriously affect human health. The prior literature has reported the biological function and potential therapeutic targets of SET domain bifurcated histone lysine methyltransferase 1 (SETDB1) as an oncogene. However, SETDB1 has rarely been analyzed from a pan-cancer perspective.

METHODS

Bioinformatics analysis tools and databases, including GeneCards, National Center for Biotechnology Information (NCBI), UniProt, Illustrator for Biological Sequences (IBS), Human Protein Atlas (HPA), GEPIA, TIMER2, Sangerbox 3.0, UALCAN, Kaplan-Meier (K-M) plotter, cBioPortal, Catalogue Of Somatic Mutations In Cancer (COSMIC), PhosphoSitePlus, TISIDB, STRING, and GeneMANIA, were utilized to clarify the biological functions and clinical significance of SETDB1 from a pan-cancer perspective.

RESULTS

In this study, the pan-cancer analysis demonstrated that SETDB1 showed significantly differential expression in most tumor tissues and paracancerous tissues, and SETDB1 expression was associated with clinicopathological features and clinical prognosis. We also found that SETDB1 mutations occurred in most tumors and were related to tumorigenesis. In addition, DNA methylation of SETDB1 primarily occurred at the cg10444928 site and was associated with prognosis in several human tumors. The predicted phosphorylation site of SETDB1 was Ser1006. We found that SETDB1 was significantly related to the specific tumor-infiltrating immune cell populations and expression of clinically targetable immune checkpoints and may be a promising immunotherapy target. The Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses also indicated that SETDB1 may function as crucial regulator in carcinogenesis of human cancers.

CONCLUSIONS

SETDB1 is an important oncogene involved in tumorigenesis and tumor progression through different biological mechanisms. Furthermore, SETDB1 may be a potential therapeutic target for cancer treatment.

摘要

背景

恶性肿瘤是严重影响人类健康的最常见疾病之一。先前的文献报道了SET结构域分叉组蛋白赖氨酸甲基转移酶1(SETDB1)作为一种癌基因的生物学功能和潜在治疗靶点。然而,很少从泛癌角度对SETDB1进行分析。

方法

利用生物信息学分析工具和数据库,包括基因卡片、美国国立生物技术信息中心(NCBI)、通用蛋白质数据库(UniProt)、生物序列插图软件(IBS)、人类蛋白质图谱(HPA)、基因表达谱交互分析工具(GEPIA)、肿瘤免疫估计资源2(TIMER2)、桑格生物信息分析平台3.0(Sangerbox 3.0)、UALCAN、卡普兰-迈耶(K-M)生存曲线分析工具、cbioportal、癌症体细胞突变目录(COSMIC)、磷酸化位点数据库(PhosphoSitePlus)、肿瘤免疫信息数据库(TISIDB)、蛋白质相互作用数据库(STRING)和基因共表达网络分析工具(GeneMANIA),从泛癌角度阐明SETDB1的生物学功能和临床意义。

结果

在本研究中,泛癌分析表明,SETDB1在大多数肿瘤组织和癌旁组织中表现出显著差异表达,且SETDB表现出显著差异表达,且SETDB1表达与临床病理特征和临床预后相关。我们还发现,SETDB1突变发生在大多数肿瘤中,且与肿瘤发生有关。此外,SETDB1的DNA甲基化主要发生在cg10444928位点,且与几种人类肿瘤的预后相关。SETDB1的预测磷酸化位点为Ser1006。我们发现,SETDB1与特定的肿瘤浸润免疫细胞群体以及临床可靶向免疫检查点的表达显著相关,可能是一个有前景的免疫治疗靶点。基因本体论(GO)和京都基因与基因组百科全书(KEGG)分析也表明,SETDB1可能在人类癌症的发生发展中起关键调节作用。

结论

SETDB1是一种重要的癌基因,通过不同的生物学机制参与肿瘤发生和肿瘤进展。此外,SETDB1可能是癌症治疗的潜在治疗靶点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/61d0/9152430/48ac20e98be4/JO2022-6115878.001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验